Review article: The role of statins in reducing perioperative cardiac risk: Physiologic and clinical perspectives

Canadian Journal of Anesthesia

Volumn 53, Issue 11, 2006, Pages 1126-1147

  Boushra, Nader N ^a   Muntazar, Muhammad ^b  

^a Lower Bucks Hospital   (United States)

^b Department of Anesthesiology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFENTANIL; AMIODARONE; ANTIFUNGAL AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; CERIVASTATIN; CYCLOSPORIN A; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; ENDOTHELIN 1; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOW DENSITY LIPOPROTEIN; MACROLIDE; MATRIX METALLOPROTEINASE; MEVALONIC ACID; MEVINOLIN; MIDAZOLAM; NITRIC OXIDE; PITAVASTATIN; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TISSUE INHIBITOR OF METALLOPROTEINASE; UNINDEXED DRUG;

ACUTE CORONARY SYNDROME; ANTIARRHYTHMIC ACTIVITY; ANTIHYPERTENSIVE ACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG CLEARANCE; DRUG COST; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; FIBRINOLYSIS; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; MEDLINE; MORBIDITY; MORTALITY; MYALGIA; MYOPATHY; PATHOPHYSIOLOGY; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; SYSTEMATIC REVIEW; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULAR ENDOTHELIUM;

ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; CORONARY DISEASE; HEART DISEASES; HUMANS; INTRAOPERATIVE COMPLICATIONS; RISK;

EID: 33751074149     PISSN: 0832610X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03022882     Document Type: Review

References (142)

1. Kertai MD, Klein J, van Urk H, Bax JJ, Poldermans D. Cardiac complications after elective major vascular surgery. Acta Anaesthesiol Scand 2003; 47: 643-54.
2. Howell SJ, Sear JW. Perioperative myocardial injury: individual and population implications. Br J Anaesth 2004; 93: 3-8.
3. Mackey WC, Fleisher LA, Haider S, et al. Perioperative myocardial ischemic injury in high-risk vascular surgery patients: incidence and clinical significance in a prospective clinical trial. J Vasc Surg 2006; 43: 533-8.
4. Corti R, Badimon JJ. Biologic aspects of vulnerable plaque. Curr Opin Cardiol 2002; 17: 616-25.
5. Dickson BC, Gotlieh AI Towards understanding acute destabilization of vulnerable atherosclerotic plaques. Cardiovasc Pathol 2003; 12: 237-48.
6. Kullo IJ, Edwards WD, Schwartz RS. Vulnerable plaque: pathobiology and clinical implications. Ann Intern Med 1998; 129: 1050-60.
7. Poldermans D, Boersma E, Bax JJ, et al. Correlation of location of acute myocardial infarct after noncardiac vascular surgery with preoperative dobutamine echocardiographic findings. Am J Cardiol 2001; 88: 1413-4.
8. Baron JF, Mundler O, Bertrand M, et al. Dipyridamole-thallium scintigraphy and gated radionuclide angiography to assess cardiac risk before abdominal aortic surgery. N Engl J Med 1994; 330: 663-9.
9. Ellis SG, Hertzer NR, Young JR, Brener S. Angiographic correlates of cardiac death and myocardial infarction complicating major nonthoracic vascular surgery. Am J Cardiol 1996; 77: 1126-8.
10. Hogue CW Jr, Stamos T, Winters KJ, Moulton M, Krucylak PE, Cooper JD. Acute myocardial infarction during lung volume reduction surgery. Anesth Analg 1999; 88: 332-4.
11. Dawood MM, Gutpa DK, Southern J, Walia A, Atkinson JB, Eagle KA. Pathology of fatal perioperative myocardial infarction: implications regarding pathophysiology and prevention. Int J Cardiol 1996; 57: 37-44.
12. Cohen MC, Aretz TH. Histological analysis of coronary artery lesions in fatal postoperative myocardial infarction. Cardiovasc Pathol 1999; 8: 133-9.
13. Lee RT, Grodzinsky AJ, Frank EH, Kamm RD, Schoen FJ. Sructure-dependent dynamic mechanical behavior of fibrous caps from human atherosclerotic plaques. Circulation 1991; 83: 1764-70.
14. Schoenhagen P, Ziada KM, Kapadia SR, Crowe TD, Nissen SE, Tuzcu EM. Extent and direction of arterial remodeling in stable versus unstable coronary syndromes: an intravascular ultrasound study. Circulation 2000; 101: 598-603.
15. Richardson PD, Davies MJ, Born GV Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet 1989; 2: 941-4.
16. Heidland UE, Strauer BE. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 2001; 104: 1477-82.
17. Yamagishi M, Terashima M, Awano, K, et al. Morphology of vulnerable coronary plaque: insights from follow-up of patients examined by intravascular ultrasound before an acute coronary syndrome. J Am Coll Cardiol 2000; 35: 106-11.
18. Anonymous. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
19. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996; 335: 1001-9.
20. Anonymous. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339: 1349-57.
21. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-8.
22. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-22.
23. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
24. Sever PS, Dahlof P, Poulter NR, et al.; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-58.
25. Bybee KA, Wright RS, Williams BA, Murphy JG, Holmes DR Jr, Kopecky SL. Effect of concomitant or very early statin administration on in-hospital mortality and reinfarction in patients with acute myocardial infarction. Am J Cardiol 2001; 87: 771-4.
26. Stenestrand U, Wallentin L; Swedish Register of Cardiac Intensive Care (RIKS-HIA). Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001 285: 430-6.
27. Aronow HD, Topol EJ, Roe MT, et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet 2001; 357: 1063-8.
28. Heeschen C, Hamm CW, Lauf U, Snapinn S, Bohm M, White HD; Platelet Receptor Inbibition in Ischemic Syndrome Management (PRISM) Investigators. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002; 105: 1446-52.
29. Saab FA, Eagle KA, Kline-Rogers E, Fang J, Otten R, Mukherjee D; Michigan Cardiovascular Outcomes Research and Reporting Program of the University of Michigan Cardiovascular Center. Comparisons of outcomes in acute coronary syndrome in patients receiving statins within 24 hours of onset versus at later times. Am J Cardiol 2004; 94: 1166-8.
30. Spencer FA, Allegrone J, Goldberg RJ, et al.; GRACE Investigators. Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study. Ann Intern Med 2004; 140: 857-66.
31. Schwartz GG, Olsson AG, Ezekowitz MD, et al.; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. the MIRACL study: a randomized controlled trial. JAMA 2001; 285: 1711-8.
32. Cannon CR, Braunwald E, McCabe CH, et al.; Pravastatin or Atorvastatin Evaluation and Infection Therapy - Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-504.
33. de Lemos JA, Blazing MA, Wiviott SD, et al.; A to Z Investigators. Early intensive vs a delayed conservative siravastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004; 292: 1307-16.
34. Li DY, Chen HJ, Mebta JL. Statins inhibit oxidized-LDL-mediated LOX-1 expression, uptake of oxidized-LDL and reduction in PKB phosphorylation. Cardiovasc Res 2001; 52: 130-5.
35. Morikawa S, Takabe W, Mataki C, et al. The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. Human umbilical vein endothelial cells. J Atheroscler Thromb 2002; 9: 178-83.
36. Mason RP, Walter MF, Jacob RF Effects of HMG-CoA reductase inhibitors on endothelial function: role of microdomains; and oxidative stress. Circulation 2004; 109(suppi II): II-34-II-41.
37. Zelvyte I, Dominaitiene R, Crisby M, Janciauskiene S. Modulation of inflammatory mediators and PPARgamma and NFkappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro. Pharmacol Res 2002; 45: 147-54.
38. Rosenson RS, Tangney CC, Levine DM, Parker TS, Gordon BR. Association between reduced low density lipoprotein oxidation and inhibition of monocyte chemoattractant protein-1 production in statin-treated subjects. J Lab Clin Med 2005; 145: 83-7.
39. Porreca E, Di Febbo C, Baccante G, Di Nisio M, Cuccurullo F. Increased transforming growth factor-beta (1) circulating levels and production in human monocytes after 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibition with pravastatin. J Am Coll Cardiol 2002,- 39: 1752-7.
40. Grandaliano G, Biswas P, Choudhury GG, Abboud HE. Simvastatin inhibits PDGF-induced DNA synthesis in human glomerular mesangial cells. Kidney Int 1993; 44: 503-8.
41. Degraeve F, Bolla M, Blaie S, et al. Modulation of COX-2 expression by statins; in human aortic smooth muscle cells. Involvement of geranylgeranylated proteins. J Biol Chem 2001; 276: 46849-55.
42. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001; 103: 926-33.
43. Fukumoto Y, Libby P, Rabkin E, et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of Watanabe heritable hyperlipidemic rabbits. Circulation 2001; 103: 993-9.
44. Viedt C, Shen W, Fei J, et al. HMG-Co A reductase inhibition reduces the proinflammatory activation of human vascular smooth muscle cells by the terminal complement factor C5b-9. Basic Res Cardiol 2003; 98: 353-61.
45. Kaneider NC, Reinisch CM, Dunzendorfer S, Meierhofer C, Djanani A, Wiedermann CJ. Induction of apoptosis and inhibition of migration of inflammatory and vascular wall cells by cerivastatin. Athersclerosis 2001; 158: 23-33.
46. Kempen HJ, Vermeer M, de Wit E, Havekes LM Vastatins inhibit cholesterol ester accumulation in human monocyte-derived macrophages. Arterioscler Thromb 1991; 11: 146-53.
47. Sakai M, Kobori S, Matsumura T, et al. HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein. Atherosclerosis 1997; 133: 51-9.
48. Martin G, Duez H, Blanquart C, et al. Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J Clin Invest 2001; 107: 1423-32.
49. Loree HM, Tobias BJ, Gibson LJ, Kamm RD, Small DM, Lee RT. Mechanical properties of model atherosclerotic lesion lipid pools. Arterioscler Thromb 1994; 14: 230-4.
50. Weis M, Heeschen C, Glassford AJ, Cooke JP. Statins have biphasic effects on angiogenesis. Circulation 2002; 105: 739-45.
51. Budoff MJ, Yu D, Nasir K, et al. Diabetes and progression of coronary calcium under the influence of statin therapy. Am Heart J 2005; 149: 695-700.
52. Cipollone F, Mezzetti A, Porreca E, et al. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation 2002; 106: 399-402.
53. Eto M, Kozai T, Cosentino F, Joch H, Luscher TF. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation 2002; 105: 1756-9.
54. Essig M, Nguyen G, Prie D, Fscoubet B, Sraer JD, Friedlander G. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranyl-geranylation and Rho proteins. Circ Res 1998; 83: 683-90.
55. Puccetti L, Sawamura T, Pasqui AL, Pastorelli M, Auteri A, Bruni F. Atorvastatin reduces platelet-oxidized-LDL receptor expression in hypercholesterolaemic patients. Eur J Clin Invest 2005; 35: 47-51.
56. John S, Delles C, Jacobi J, et al. Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cenvastatin within two weeks. J Am Coll Cardiol 2001; 37: 1351-8.
57. Masumoto A, Hirooka Y, Hironaga K, et al. Effect of pravastatin on endothelial function in patients with coronary artery disease (cholesterol-independent effect of pravastatin). Am J Cardiol 2001; 88: 1291-4.
58. Dupuis J, Tardif JC, Cernacek P Theroux P Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 1999; 99: 3227-33.
59. Houghton JL, Pearson TA, Reed RG, et al. Cholesterol lowering with pravastatin improves resistance artery endothelial function: report of six subjects with normal coronary arteriograms. Chest 2000; 118: 756-60.
60. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995; 332: 481-7.
61. Bickel C, Rupprecht HJ, Blankenberg S, et al. Influence of HMG-CoA reductase inhibitors on markers of coagulation, systemic inflammation and soluble cell adhesion. Int J Cardiol 2002; 82: 25-31.
62. Mostaza JM, Gomez MV, Gallardo F, et al.; AtheroGene Group. Cholesterol reduction improves myocardial perfusion abnormalities in patients with coronary artery disease and average cholesterol levels. J Am Coll Cardiol 2000; 35: 76-82.
63. Corti R, Fayad ZA, Fuster V, et al. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation 2001; 104: 249-52.
64. Jensen LO, Thayssen P, Pedersen KE, Stender S, Haghfelt T. Regression of coronary atherosclerosis by simvastatin: a serial intravascular ultrasound study. Circulation 2004; 110: 265-70.
65. Molloy KJ, Thompson MM, Schwalbe EC, Bell PR, Naylor AR, Loftus IM. Comparison of levels of matrix metalloproteinases, tissue inhibitor of metalloproteinases, interleukins, and tissue necrosis factor in carotid endarterectomy specimens from patients on versus not on statins preoperatively. Am J Cardiol 2004; 94: 144-6.
66. Undas A, Brummel-Ziedins KE, Mann KG. Statins and blood coagulation. Arterioscler Thromb Vasc Biol 2005; 25: 287-94.
67. Undas A, Brummel KE, Musial J Mann KG, Szczeklik A. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation 2001; 103: 2248-53.
68. Son JW, Koh KK, Ahn JY, et al. Effects of statin on plaque stability and thrombogenicity in hypercholesterolemic patients with coronary artery disease. Int J Cardiol 2003; 88: 77-82.
69. Cortellaro M, Cofrancesco E, Arbustini E, et al. Atorvastatin and thrombogenicity of the carotid atherosclerotic plaque: the ATROCAP study. Thromb Haemost 2002; 88: 41-7.
70. Landesburg G. The pathophysiology of perioperative myocardial infarction: facts and perspectives. J Cardiothorac Vasc Anesth 2003; 17: 90-100.
71. Priebe HJ. Triggers of perioperative myocardial ischaemia and infarction. Br J Anaesth 2004, 93: 9-20.
72. Sametz W, Metzler H, Gries M, et al. Perioperative catecholamine changes in cardiac risk patients. Eur J Clin Invest 1999; 29: 582-7.
73. Mangano DT. Assessment of the patient with cardiac disease: an anesthesiologist's paradigm. Anesthesiology 1999; 91: 1521-6.
74. Rosenfeld BA, Beattie C, Christopherson R, et al. The effects of different anesthetic regimens on fibrinolysis and the development of postoperative arterial thrombosis. Perioperative Ischemia Randomized Anesthesia Trial Study Group. Anesthesiology 1993; 79: 435-43.
75. Samama CM, Thiry D, Elalamy I, et al. Perioperative activation of hemostasis in vascular surgery patients. Anesthesiology 2001; 94: 74-8.
76. Wayhs R, Zelinger A, Raggi P. High coronary artery calcium scores pose an extremely elevated risk for hard events. J Am Coll Cardiol 2002; 39: 225-30.
77. Mahla E, Vicenzi MY, Schrottner B, et al. Coronary artery plaque burden and perioperative cardiac risk. Anesthesiology 2001; 95: 1133-40.
78. Spagnoli LG, Bonanno E, Mauriello A, et al. Multicentric inflammation in epicardial coronary arteries of patients dying of acute myocardial infarction. J Am Coll Cardiol 2002; 40: 1579-88.
79. Abbate A, Bonanno E, Mauriello A, et al. Widespread myocardial inflammation and infarct-related artery patency. Circulation 2004; 110: 46-50.
80. Rioufol G, Finet G, Ginon I, et al. Multiple atherosclerotic plaque rupture in acute coronary syndrome: a three-vessel intravascular ultrasound study. Circulation 2002; 106: 804-8.
81. Asakura M, Ueda Y, Yamaguchi O, et al. Extensive development of vulnerable plaques as a pan-coronary process in patients with myocardial infarction: an angioscopic study. J Am Coll Cardiol 2001; 37: 1284-8.
82. Goldstein JA, Demetriou D, Grines CL, Pica M, Shoukfeh M, O'Neill WW. Multiple complex coronary plaques in patients with acute myocardial infarction. N Engl J Med 2000; 343: 915-22.
83. Zairis MY, Papadaki OA, Manousakis SJ, et al. C-reactive protein and multiple complex coronary artery plaques in patients with primary unstable angina. Atherosclerosis 2002; 164: 355-9.
84. Burke AP, Tracy RP, Kolodgie F, et al. Elevated C-reactive protein values and atherosclerosis in sudden coronary death: association with different pathologies. Circulation 2002; 105: 2019-23.
85. Biancari F, Lahtinen J, Lepojarvi S, et al. Preoperative C-reactive protein and outcome after coronary artery bypass surgery. Ann Thorac Surg 2003, 76: 2007-12.
86. Walter DH, Fichtlscherer S, Sellwig M, Auch-Schwelk W, Schachinger V, Zeiher AM. Preprocedural. C-reactive protein levels and cardiovascular events after coronary stent implantation. J Am Coll Cardiol 2001; 37: 839-46.
87. London MJ, Zaugg M, Schaub MC, Spahn DR. Perioperative β-adrenergic receptor blockade: physiologic foundations and clinical controversies. Anesthesiology 2004, 100: 170-5.
88. Eagle KA, Berger PB, Calkins H, et al. ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery: executive summary: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). Circulation 2002; 105: 1257-67.
89. Wallace A, Layug B, Tateo I, et al. Prophylactic atenolol reduces postoperative myocardial ischemia. McSPI Research Group. Anesthesiology 1998; 88: 7-17.
90. Boersma E, Poldermans D, Bax JJ, et al.; DECREASE Study Group (Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography). Predictors of cardiac events after major vascular surgery: role of clinical characteristics, dobutamine echocardiography, and beta-blocker therapy. JAMA 2001; 285: 1865-73.
91. Lindenauer PK, Pekow P, Wang K, Mamidi DK, Gutierrez B, Benjamin EM. Perioperative beta-blockade therapy and mortality after major noncardiac surgery. N Engl J Med 2005; 353: 349-61.
92. Hedblad B, Wikstrand J, Janzon L Wedel H, Berglund G. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: main results from the β- Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation 2001; 103: 1721-6.
93. Wiklund O, Hulthe J, Wikstrand J, Schmidt C, Olofsson SO, Bondjers G. Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year randomized study. Stroke 2002; 33: 572-7.
94. Hognestad A, Dickstein K, Myhre E, Snapinn S, Kjekshus J; OPTIMAAL Investigators. Effect of combined statin and beta-blocker treatment on one-year morbidity and mortality after acute myocardial infarction associated with heart failure. Am J Cardiol 2004; 93: 603-6.
95. Poldermans D, Bax JJ, Kertai MD, et al. Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. Circulation 2003; 107: 1848-51.
96. Kertai MD, Boersma E, Westerhout CM, et al. A combination of statins and beta-blockers is independently associated with a reduction in the incidence of perioperative mortality and nonfatal myocardial infarction in patients undergoing abdominal aortic aneurysm surgery. Eur J Vasc Endovasc Surg 2004; 28: 343-52.
97. Kertai MD, Boersma E, Westerhout CM, et al. Association between long-term statin use and mortality after successful abdominal aortic aneurysm surgery. Am J Med 2004; 116: 96-103.
98. Durazzo AE, Machado FS, Ikeoka DT, et al. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. J Vasc Surg 2004; 39: 967-76.
99. O'Neil-Callahan K, Katsimaglis G, Tepper MR, et al. Statins decrease perioperative cardiac complications in patients undergoing noncardiac vascular surgery: the Statins for Risk Reduction in Surgery (StaRRS) study. J Am Coll Cardiol. 2005; 45: 336-42.
100. Lindenauer PK, Pekow P, Wang K, Gutierrez B, Benjamin EM. Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery. JAMA 2004; 291: 2092-9.
101. Schouten O, Kertai MD, Bax JJ, et al. Safety of perioperative statin use in high-risk patients undergoing major vascular surgery. Am J Cardiol 2005; 95: 658-60.
102. Ward RP, Leeper NJ, Kirkpatrick JN, Lang RM, Sorrentino MJ, Williams KA. The effect of preoperative statin. therapy on cardiovascular outcomes in patients undergoing infrainguinal vascular surgery. Int J Cardiol 2005; 104: 264-8.
103. Schouten O, van Laanen JHH, Boersma E, et al. Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth. Eur J Vasc Endovasc Surg 2006; 32: 21-6.
104. Schouten O, Kok NF, Boersma E, et al. Effects of statins on renal function after aortic cross damping during major vascular surgery. Am J Cardiol 2006; 97: 1383-5.
105. Henke PK, Blackburn S, Proctor MC, et al. Patients undergoing infrainguinal bypass to treat atherosclerotic vascular disease are underprescribed cardioprotective medications: effect on graft patency, limb salvage, and mortality. J Vasc Surg 2004; 39: 357-65.
106. Abbruzzese TA, Havens J, Belkin M, et al. Statin therapy is associated with improved patency of autogenous infrainguinal bypass grafts. J Vasc Surg 2004; 39: 1178-85.
107. LaMuraglia GM, Stoner MC, Brewster DC, et al. Determinants of carotid endarterectomy anatomic durability: effects of serum hpids and lipid-lowering drugs. J Vasc Surg 2005; 41: 762-8.
108. Kennedy J, Quan H, Buchan AM, Ghali WA, Feasby TE. Statins are associated with better outcomes after carotid endarterectomy in symptomatic patients. Stroke 2005; 36: 2072-6.
109. Chan AW, Bhatt DL, Chew DP, et al. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 2002; 105: 691-6.
110. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G; ARMYDA Investigators. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of Myocardial Damage during Angioplasty) study. Circulation 2004; 110: 674-8.
111. Clark LL Ikonomidis JS, Crawford FA Jr, et al. Preoperative statin treatment is associated with reduced postoperative mortality and morbidity in patients undergoing cardiac surgery: an 8-year retrospective cohort study. J Thorac Cardiovasc Surg 2006; 131: 679-85.
112. Pascual DA, Arribas JM, Tornel PL, et al. Preoperative statin therapy and troponin T predict early complications of coronary artery surgery. Ann Thorac Surg 2006; 81: 78-84.
113. Ali IS, Buth KJ. Preoperative statin use and outcomes following cardiac surgery. Int J Cardiol 2005; 103: 12-8.
114. Landesberg G, Mosseri M, Wolf YG, et al. Preoperative thallium scanning, selective coronary revascularization, and long-term survival after major vascular surgery. Circulation 2003; 108: 177-83.
115. Nette AF, Abraham G, Ungemacg FR, et al. Interaction between simvastatin and metoprolol with respect to cardiac β-adrenoreceptor density, catecholamine levels and perioperative catecholamine requirements in cardiac surgery patients. Naunyn Schmiedeberg's Arch Pharmacol 2005; 372: 115-24.
116. Bristow MR. β-Adrenergic receptor blockade in chronic heart failure. Circulation 2000; 101: 558-69.
117. Schouten O, Poldermans D. Statins in the prevention of perioperative cardiovascular complications. Curr Opin Anaesthesiol 2005; 18: 51-5.
118. Schouten O, Poldermans D, Vaser L, et al. Fluvastatin and bisoprolol for the reduction of perioperative cardiac mortality and morbidity in high-risk patients undergoing non-cardiac surgery: rationale and design of the DECREASE-IV study. Am Heart J 2004; 148: 1047-52.
119. Lalouschek W, Lang W, Greisenegger S, Mullner M; Vienna Stroke Study Group. Determination of lipid profiles and use of statins in patients with ischemic stroke or transient ischemic attack. Stroke 2003; 34: 105-10.
120. Grodzinska L, Starzyk D, Bieron K, Goszcz A, Korbut R. Simvastatin effects in normo- and hypercholesterolaemic patients with peripheral arterial occlusive disease: a pilot study. Basic Clin Pharmacol Toxicol 2005; 96: 413-9.
121. Schillinger M, Exner M, Mlekusch W, et al. Statin therapy improves cardiovascular outcome of patients with peripheral artery disease. Eur Heart J 2004; 25: 742-8.
122. Deedwania PC, Hunninghake DB, Bays HE, Jones PH, Cain VA, Blasetto JW, STELLAR Study Group. Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome. Am J Cardiol 2005; 95: 360-6.
123. Burke AP, Kolodgie FD, Farh A, et al. Heated plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression. Circulation 2001; 103: 934-40.
124. Biccard BM, Sear JW, Foëc P Statin therapy: a potentially useful peri-operative intervention in patients with cardiovascular disease. Anaesthesia 2005; 60: 1106-14.
125. Caravalho J Jr, O'Donnell SD, Feuerstein IM, et al. Preoperative risk stratification using electron beam computed tomography in elective vascular surgery: relationship to clinical risk prediction and postoperative complications. Ann Vasc Surg 2002; 16: 639-43.
126. Grundy SM, Cleeman JI, Merz CN, et al.; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-39.
127. Mora S, Ridker PM. Justification for the use of statins in primary prevention: an intervention trial evaluating rosuvastatin (JUPITER) - can C-reactive protein be used to target statin therapy in primary prevention? Am J Cardiol 2006; 97: 33A-41A.
128. Brewer HB Jr. Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am J Cardiol 2003; 92: 23K-9K.
129. McDonnell CG, Harte S, O'Driscoll J, O'Loughlin C, Van Pelt FD, Shorten GD. The effects of concurrent atorvastatin therapy on the pharmacokinetics of intravenous midazolam. Anaesthesia 2003; 58: 899-904.
130. McDonnell CG, Malkan D, Van Pelt FD, Shorten GD. Elimination of alfentanil delivered by infusion is not altered by the chronic administration of atorvastatin. Eur J Anaesthesiol 2003; 20: 662-7.
131. Roten L, Schoenenberger RA, Krahenbuhl S. Schlienger RG. Rhabdomyolysis in association with simvastatin and amiodarone. Ann Pharmacother 2004; 38: 978-81.
132. John S, Schneider MP, Delles C, Jacobi J, Schmieder RE. Lipid-independcnt effects of statins; on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. Am Heart J 2005; 149: 473.
133. Wassmann S, Faul A, Hennen B, Scheller B, Bohm M, Nickeniq G. Rapid effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition on coronary endothelial function. Circ Res 2003; 93: e98-e103.
134. Gokce N, Keaney JF Jr, Hunter LM, Watkins MT, Menzoian JO, Vita JA. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation 2002; 105: 1567-72.
135. Steiner S, Speidl WS, Pleiner J, et al. Simvastatin blunts endotoxin-induced tissue factor in vivo. Circulation 2005; 111: 1841-6.
136. Biccard BM, Sear JW, Foex P. The pharmaco-economics of peri-operative statin therapy. Anaesthesia 2005; 60: 1059-63.
137. Forestier F, Breton Y, Bonnet E, Janvier G. Severe rhabdomyolysis after laparoscopic surgery for adenocarcinoma of the rectum in two patients treated with statins. Anethesiology 2002; 97: 1019-21.
138. Wilhelmi M, Winterhalter M, Fischer S, et al. Massive postoperative rhabdomyolysis following combined CABG/abdominal aortic replacement: a possible association with HMG-CoA reductase inhibitors. Cardiovasc Drugs Ther 2002; 16: 471-5.
139. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C; American College of Cardiology; American Heart Association; National Heart, Lung, and Blood Institute. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation 2002; 106: 1024-8.
140. McGowan MP; Treating to New Target (TNT) Study Group. There is no evidence for an increase in acute coronary syndromes after short-term abrupt discontinuation of statin in stable cardiac patients. Circulation 2004; 110: 2333-5.
141. Krivosic-Horber R, Depret T, Wagner JM, Maurage CA. Malignant hyperthermia susceptibility revealed by increased serum creatine kinase concentrations during statin treatment. Eur J Anaesthesiol 2004; 21: 572-4.
142. Guis S, Bendahan D, Kozak-Ribbens G, et al. Rhabdomyolysis and myalgia associated with anticholesterolemic treatment as potential signs of malignant hyperthermia susceptibility. Arthritis Rheum 2003; 49: 237-8.